Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava: Report of 2 cases

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 15, Issue 5, 2013, Pages

  Toohey, Tara Pundiak ^a,b   Lu, Brett Y ^a   Wada, Cherisse ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUMAZENIL; HALOPERIDOL; KAVA; LORAZEPAM; QUETIAPINE; ROPINIROLE;

ACUTE PSYCHOSIS; AGED; AGGRESSION; ARTICLE; BEDTIME DOSAGE; BIPOLAR II DISORDER; CASE REPORT; DISEASE COURSE; DRUG INDUCED DISEASE; EMERGENCY WARD; ENZYME INHIBITION; FEMALE; FLUID INTAKE; HEART ATRIUM FLUTTER; HUMAN; HYPOXIA; INTENSIVE CARE; LOW DRUG DOSE; MALE; MANIA; PARANOIA; RESTLESS LEGS SYNDROME; TRADITIONAL MEDICINE; VISUAL HALLUCINATION;

EID: 84888099228     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13br01539     Document Type: Article

References (11)

1. Kava. In: DerMarderosian A, Beutler JA, eds. The Review of Natural Products. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
2. Kava: Losing Tradition Through Abuse. Coalition for a Drug Free Hawaii Web site. http://www.drugfreehawaii.org/files/June2006.pdf. Updated July 3, 2006. Accessed July 14, 2012.
3. Rowe A, Zhang LY, Ramzan I. Toxicokinetics of kava. Adv Pharmacol Sci. 2011;2011:326724. PubMed Show Abstract Show Abstract
4. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos. 2002;30(11):1153-1157. PubMed doi:10.1124/dmd.30.11.1153 Show Abstract Show Abstract
5. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002;71(13):1579-1589. PubMed doi:10.1016/S0024-3205(02)01913-6 Show Abstract Show Abstract
6. Yuan CS, Dey L, Wang A, et al. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med. 2002;68(12):1092-1096. PubMed doi:10.1055/s-2002-36338 Show Abstract Show Abstract
7. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St John's wort, and echinacea. Mol Nutr Food Res. 2008;52(7):755-763. PubMed doi:10.1002/mnfr.200600300 Show Abstract Show Abstract
8. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426. PubMed doi:10.1016/j.clpt.2005.01.009 Show Abstract Show Abstract
9. Russmann S, Barguil Y, Cabalion P, et al. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther. 2005;77(5):453-454. doi:10.1016/j.clpt.2005.01.021 PubMed
10. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med. 2012;78(13):1490-1514. PubMed doi:10.1055/s-0031-1298331 Show Abstract Show Abstract
11. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol. 2004;93(2-3):153-160. PubMed doi:10.1016/j.jep.2004.04.009 Show Abstract Show Abstract